ELVN
Enliven Therapeutics Inc

1,246
Mkt Cap
$1B
Volume
1.2M
52W High
$25.37
52W Low
$13.30
PE Ratio
-8.68
ELVN Fundamentals
Price
$16.02
Prev Close
$16.91
Open
$16.95
50D MA
$20.55
Beta
1.40
Avg. Volume
660,406.84
EPS (Annual)
-$1.89
P/B
1.99
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN
5AM Venture Management LLC reduced its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 41.6% in the 2nd quarter, according to the company in its most recent 13F filing...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,663 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average...
MarketBeat·6d ago
News Placeholder
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules PR Newswire BOULDER...
PR Newswire·6d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% on Insider Selling...
MarketBeat·7d ago
News Placeholder
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 6,663 Shares of Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,663 shares of the company's stock in a transaction on Monday, December 8th. The stock was sold at an average price of...
MarketBeat·7d ago
News Placeholder
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development Enliven Therapeutics Announces New CEO to Drive Next Phase of Development PR Newswire BOULDER, Colo., Dec. 11, 2025 Rick...
PR Newswire·7d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Here's What Happened
Enliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading Volume - Time to Buy...
MarketBeat·8d ago
News Placeholder
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has received an average rating of "Moderate Buy" from the six research firms that are presently covering the company, Marketbeat reports...
MarketBeat·10d ago
News Placeholder
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 101.3% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·15d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8% - Time to Sell?
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 8% - Should You Sell...
MarketBeat·15d ago
<
1
2
...
>

Latest ELVN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.